AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

NORTH CHICAGO, Ill. and MENLO PARK, Calif., Feb. 11, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV),  Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Original Source